Top

International Urology and Nephrology

Published in:

16-10-2023 | Erectile Dysfunction | Urology - Original Paper

Novel anthropometric measures are positively associated with erectile dysfunction: a cross-sectional study

Authors: Weilong Lin, Ming-En Lin

Published in: International Urology and Nephrology | Issue 3/2024

Abstract

Background

Currently, a growing number of research studies have shown a positive association between obesity and erectile dysfunction, while traditional anthropometric measures, such as BMI, have limited ability to assess the risk of erectile dysfunction. Therefore, this study aimed to investigate the association between the new anthropometric index and erectile dysfunction.

Methods

A study involving 3594 participants from the National Health and Nutrition Examination Survey was conducted. The study calculated various anthropometric indices such as waist circumference (WC), waist-to-height ratio (WtHR), body mass index (BMI), a body shape index (ABSI), conicity index (CI), and body roundness index (BRI). The relationship between anthropometric indices and erectile dysfunction (ED) was investigated using multivariate logistic regression and restricted cubic splines (RCS). Interaction analysis was conducted on subgroups to confirm the findings. Additionally, the efficacy of various anthropometric indicators in predicting the risk of erectile dysfunction was assessed using the receiver operating characteristic curve (ROC).

Results

After adjusting for potential confounding factors, we identified a positive and independent correlation between erectile dysfunction (ED) and all other anthropometric measures except for BMI. Additionally, the risk of ED increased by 49% and 42% for each standard deviation increment in ABSI and CI, respectively. Dose—response curve analysis demonstrated that WC, BMI, WtHR, and CI displayed a non-linear correlation with the risk of ED. The subgroup analysis revealed that individuals classified as White, who had higher levels of WC, ABSI, and CI, were more susceptible to erectile dysfunction compared to people from other races. ROC analysis showed that ABSI was superior in detecting erectile dysfunction (area under the curve: 0.750; 95% CI 0.732–0.768; optimal cutoff value: 0.083) as compared to other indices. The combination of obesity defined by BMI and other anthropometric measures showed that higher ABSI and CI levels were positively associated with the prevalence of erectile dysfunction, independent of BMI (P < .001).

Conclusion

In this study, anthropometric indicators including ABSI, BRI, WtHR, CI, and WC were positively associated with erectile dysfunction. To improve the prevention and treatment of this condition, it is recommended that new anthropometric indicators receive greater consideration.

Available only for authorised users

Eid JF, Nehra A, Andersson KE et al (2000) First International Conference on the management of erectile dysfunction. Overview consensus statement. Int J Impot Res 12 Suppl 4:S2-5. https://doi.org/10.1038/sj.ijir.3900600CrossRefPubMed

Selvin E, Burnett AL, Platz EA (2007) Prevalence and risk factors for erectile dysfunction in the US. Am J Med 120(2):151–157. https://doi.org/10.1016/j.amjmed.2006.06.010CrossRefPubMed

Johannes CB, Araujo AB, Feldman HA et al (2000) Incidence of erectile dysfunction in men 40 to 69 years old: longitudinal results from the massachusetts male aging study. J Urol 163(2):460–463CrossRefPubMed

Ponholzer A, Temml C, Mock K et al (2005) Prevalence and risk factors for erectile dysfunction in 2869 men using a validated questionnaire. Eur Urol 47(1):80–85. https://doi.org/10.1016/j.eururo.2004.08.017CrossRefPubMed

Andersson DP, Trolle Lagerros Y, Grotta A et al (2017) Association between treatment for erectile dysfunction and death or cardiovascular outcomes after myocardial infarction. Heart 103(16):1264–1270. https://doi.org/10.1136/heartjnl-2016-310746CrossRefPubMed

Zhong L, Ding W, Zeng Q et al (2020) Sodium tanshinone iia sulfonate attenuates erectile dysfunction in rats with hyperlipidemia. Oxid Med Cell Longev 2020:7286958. https://doi.org/10.1155/2020/7286958CrossRefPubMedPubMedCentral

Yafi FA, Jenkins L, Albersen M et al (2016) Erectile dysfunction. Nat Rev Dis Primers 2(1):1–20. https://doi.org/10.1038/nrdp.2016.3CrossRef

Pizzol D, Smith L, Fontana L et al (2020) Associations between body mass index, waist circumference and erectile dysfunction: a systematic review and meta-analysis. Rev Endocr Metab Disord 21(4):657–666. https://doi.org/10.1007/s11154-020-09541-0CrossRefPubMed

Janiszewski PM, Janssen I, Ross R (2009) Abdominal obesity and physical inactivity are associated with erectile dysfunction independent of body mass index. J Sex Med 6(7):1990–1998. https://doi.org/10.1111/j.1743-6109.2009.01302.xCrossRefPubMed

10.

Janssen I, Katzmarzyk PT, Ross R (2004) Waist circumference and not body mass index explains obesity-related health risk. Am J Clin Nutr 79(3):379–384. https://doi.org/10.1093/ajcn/79.3.379CrossRefPubMed

11.

Ashwell M, Gunn P, Gibson S (2012) Waist-to-height ratio is a better screening tool than waist circumference and bmi for adult cardiometabolic risk factors: systematic review and meta-analysis. Obes Rev 13(3):275–286. https://doi.org/10.1111/j.1467-789X.2011.00952.xCrossRefPubMed

12.

Krakauer NY, Krakauer JC (2012) A new body shape index predicts mortality hazard independently of body mass index. PLoS ONE 7(7):e39504. https://doi.org/10.1371/journal.pone.0039504ADSCrossRefPubMedPubMedCentral

13.

Biolo G, Girolamo FGD, Breglia A et al (2015) Inverse relationship between “a Body Shape Index” (ABSI) and fat-free mass in women and men: insights into mechanisms of sarcopenic obesity. Clin Nutr 34(2):323–327. https://doi.org/10.1016/j.clnu.2014.03.015CrossRefPubMed

14.

Thomas DM, Bredlau C, Bosy-Westphal A et al (2013) Relationships between body roundness with body fat and visceral adipose tissue emerging from a new geometrical model. Obesity 21(11):2264–2271. https://doi.org/10.1002/oby.20408CrossRefPubMed

15.

Liu Y, Liu X, Guan H et al (2021) Body roundness index is a superior obesity index in predicting diabetes risk among hypertensive patients: a prospective cohort study in China. Front Cardiovasc Med 8:736073. https://doi.org/10.3389/fcvm.2021.736073CrossRefPubMedPubMedCentral

16.

Valdez R (1991) A simple model-based index of abdominal adiposity. J Clin Epidemiol 44(9):955–956. https://doi.org/10.1016/0895-4356(91)90059-ICrossRefPubMed

17.

Motamed N, Perumal D, Zamani F et al (2015) Conicity index and waist-to-hip ratio are superior obesity indices in predicting 10-year cardiovascular risk among men and women. Clin Cardiol 38(9):527–534. https://doi.org/10.1002/clc.22437CrossRefPubMedPubMedCentral

18.

Derby CA, Araujo AB, Johannes CB et al (2000) Measurement of erectile dysfunction in population-based studies: the use of a single question self-assessment in the massachusetts male aging study. Int J Impot Res 12(4):197–204. https://doi.org/10.1038/sj.ijir.3900542CrossRefPubMed

19.

Liu Y, Hu X, Xiong M et al (2023) Association of BMI with erectile dysfunction: a cross-sectional study of men from an andrology clinic. Front Endocrinol (Lausanne) 14:1135024. https://doi.org/10.3389/fendo.2023.1135024CrossRefPubMed

20.

21.

Yassin AA, Nettleship JE, Salman M et al (2017) Waist circumference is superior to weight and bmi in predicting sexual symptoms, voiding symptoms and psychosomatic symptoms in men with hypogonadism and erectile dysfunction. Andrologia. https://doi.org/10.1111/and.12634CrossRefPubMed

22.

Riedner CE, Rhoden EL, Ribeiro EP et al (2006) Central obesity is an independent predictor of erectile dysfunction in older men. J Urol 176(4 Pt 1):1519–1523. https://doi.org/10.1016/j.juro.2006.06.049CrossRefPubMed

23.

Lue TF (2000) Erectile dysfunction. N Engl J Med 342(24):1802–1813. https://doi.org/10.1056/NEJM200006153422407CrossRefPubMed

24.

Burnett AL (1997) Nitric oxide in the penis: physiology and pathology. J Urol 157(1):320–324CrossRefPubMed

25.

Hutley L, Prins JB (2005) Fat as an endocrine organ: relationship to the metabolic syndrome. Am J Med Sci 330(6):280–289. https://doi.org/10.1097/00000441-200512000-00005CrossRefPubMed

26.

Trayhurn P, Wood IS (2004) Adipokines: inflammation and the pleiotropic role of white adipose tissue. Br J Nutr 92(3):347–355. https://doi.org/10.1079/bjn20041213CrossRefPubMed

27.

Lyon CJ, Law RE, Hsueh WA (2003) Minireview: adiposity, inflammation, and atherogenesis. Endocrinology 144(6):2195–2200. https://doi.org/10.1210/en.2003-0285CrossRefPubMed

28.

Jang Y, Kim OY, Ryu HJ et al (2003) Visceral fat accumulation determines postprandial lipemic response, lipid peroxidation, dna damage, and endothelial dysfunction in nonobese korean men. J Lipid Res 44(12):2356–2364. https://doi.org/10.1194/jlr.M300233-JLR200CrossRefPubMed

29.

Erectile Physiological and Pathophysiological Pathways Involved in Erectile Dysfunction. J Urol. https://www.auajournals.org/doi/https://doi.org/10.1097/01.ju.0000075362.08363.a4. Accessed 2023–05–23.

30.

Allen NE, Appleby PN, Davey GK et al (2002) Lifestyle and nutritional determinants of bioavailable androgens and related hormones in british men. Cancer Causes Control 13(4):353–363. https://doi.org/10.1023/a:1015238102830CrossRefPubMed

31.

Aggerholm AS, Thulstrup AM, Toft G et al (2008) Is overweight a risk factor for reduced semen quality and altered serum sex hormone profile? Fertil Steril 90(3):619–626. https://doi.org/10.1016/j.fertnstert.2007.07.1292CrossRefPubMed

32.

Corona G, Mannucci E, Fisher AD et al (2008) Low levels of androgens in men with erectile dysfunction and obesity. J Sex Med 5(10):2454–2463. https://doi.org/10.1111/j.1743-6109.2008.00856.xCrossRefPubMed

33.

Yassin A, Nettleship JE, Talib RA et al (2016) Effects of testosterone replacement therapy withdrawal and re-treatment in hypogonadal elderly men upon obesity, voiding function and prostate safety parameters. Aging Male 19(1):64–69. https://doi.org/10.3109/13685538.2015.1126573CrossRefPubMed

34.

Williams G (2012) Aromatase up-regulation, insulin and raised intracellular oestrogens in men, induce adiposity, metabolic syndrome and prostate disease, via aberrant er-α and gper signalling. Mol Cell Endocrinol 351(2):269–278. https://doi.org/10.1016/j.mce.2011.12.017CrossRefPubMed

35.

Traish AM, Munarriz R, O’Connell L et al (2003) Effects of medical or surgical castration on erectile function in an animal model. J Androl 24(3):381–387. https://doi.org/10.1002/j.1939-4640.2003.tb02686.xCrossRefPubMed

36.

Inman BA, Sauver JLS, Jacobson DJ et al (2009) A population-based, longitudinal study of erectile dysfunction and future coronary artery disease. Mayo Clin Proc 84(2):108–113. https://doi.org/10.4065/84.2.108CrossRefPubMedPubMedCentral

37.

Thompson IM, Tangen CM, Goodman PJ et al (2005) Erectile dysfunction and subsequent cardiovascular disease. JAMA 294(23):2996–3002. https://doi.org/10.1001/jama.294.23.2996CrossRefPubMed

38.

Foresta C, Caretta N, Lana A et al (2006) Reduced number of circulating endothelial progenitor cells in hypogonadal men. J Clin Endocrinol Metab 91(11):4599–4602. https://doi.org/10.1210/jc.2006-0763CrossRefPubMed

39.

Grier T, Canham-Chervak M, Sharp M et al (2015) Does body mass index misclassify physically active young men. Prev Med Rep 2:483–487. https://doi.org/10.1016/j.pmedr.2015.06.003CrossRefPubMedPubMedCentral

40.

Batsis JA, Villareal DT (2018) Sarcopenic obesity in older adults: aetiology, epidemiology and treatment strategies. Nat Rev Endocrinol 14(9):513–537. https://doi.org/10.1038/s41574-018-0062-9CrossRefPubMedPubMedCentral

41.

Rimm EB, Stampfer MJ, Giovannucci E et al (1995) Body size and fat distribution as predictors of coronary heart disease among middle-aged and older us men. Am J Epidemiol 141(12):1117–1127. https://doi.org/10.1093/oxfordjournals.aje.a117385CrossRefPubMed

42.

Bouchi R, Asakawa M, Ohara N et al (2016) Indirect measure of visceral adiposity “a body shape index” (absi) is associated with arterial stiffness in patients with type 2 diabetes. BMJ Open Diabetes Res Care 4(1):e000188. https://doi.org/10.1136/bmjdrc-2015-000188CrossRefPubMedPubMedCentral

43.

Biolo G, Di Girolamo FG, Breglia A et al (2015) Inverse relationship between “a body shape index” (ABSI) and fat-free mass in women and men: insights into mechanisms of sarcopenic obesity. Clin Nutr 34(2):323–327. https://doi.org/10.1016/j.clnu.2014.03.015CrossRefPubMed

44.

Shoji K, Maeda K, Nakamura T, Measurement of Visceral Fat by Abdominal Bioelectrical Impedance Analysis Is Beneficial in Medical Checkup. Obes Res Clin Pract, et al (2008) 2 (4). I-II. https://doi.org/10.1016/j.orcp.2008.09.001CrossRef

45.

Tate J, Knuiman M, Davis WA et al (2020) A Comparison of obesity indices in relation to mortality in type 2 diabetes: the fremantle diabetes study. Diabetologia 63(3):528–536. https://doi.org/10.1007/s00125-019-05057-8CrossRefPubMed

46.

Roriz AKC, Passos LCS, de Oliveira CC et al (2014) Evaluation of the accuracy of anthropometric clinical indicators of visceral fat in adults and elderly. PLoS ONE 9(7):e103499. https://doi.org/10.1371/journal.pone.0103499ADSCrossRefPubMedPubMedCentral

47.

Pinho CPS, Diniz AS, de Arruda IKG et al (2017) Predictive models for estimating visceral fat: the contribution from anthropometric parameters. PLoS One 12(7):178958. https://doi.org/10.1371/journal.pone.0178958CrossRef

48.

Pitanga FJG, Lessa I (2005) Anthropometric indexes of obesity as an instrument of screening for high coronary risk in adults in the city of Salvador–Bahia. Arq Bras Cardiol 85(1):26–31. https://doi.org/10.1590/s0066-782x2005001400006CrossRefPubMed

Title: Novel anthropometric measures are positively associated with erectile dysfunction: a cross-sectional study
Authors: Weilong Lin
Ming-En Lin
Publication date: 16-10-2023
Publisher: Springer Netherlands
Keywords: Erectile Dysfunction
Obesity
Obesity
Published in: International Urology and Nephrology / Issue 3/2024
Print ISSN: 0301-1623
Electronic ISSN: 1573-2584
DOI: https://doi.org/10.1007/s11255-023-03840-6

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 3/2024

Profile of chronic kidney disease from a nephrology underserviced region in North Eastern India: a preliminary report from a single center in Assam

Bibliometric study and review of Klotho research: global characteristics and trends from 2000 to 2023

Development and validation of a model for predicting the risk of prostate cancer

Associations between contrast-enhanced ultrasound features and WHO/ISUP grade of clear cell renal cell carcinoma: a retrospective study

Robotic ureteral reconstruction with colorectal mucosa graft onlay: a novel, minimally invasive technique

A modified sling mid-urethral suspension + subcutaneous tunnel-double point fixation technique for male stress urinary incontinence: a pilot study

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials